Observational cohort study of switching warfarin sodium products in a managed care organization

American Journal of Health-System Pharmacy

Volumn 57, Issue 5, 2000, Pages 452-455

  Swenson, Claudia N ^a,b   Fundak, Grodzana ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c Puget Sound Cooperative Health   (United States)

Author keywords

Anticoagulants; Equivalency; Generic; International normalized ratio; Managed care systems; Substitution; Warfarin sodium

Indexed keywords

GENERIC DRUG; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0034161566     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.5.452     Document Type: Article

References (6)

1. FDA position on product selection for 'narrow therapeutic index' drugs. Am J Health-Syst Pharm. 1997; 54:1630-2.
2. Neutel JM, Smith DHG. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Rep. 1998; 19(2):49-52,55-9.
3. Neutel JM, Smith DHG. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Erratum. Cardiovasc Rev Rep. 1998; 19(3):11.
4. Handler J, Nguyen TT, Rush S et al. A blinded, randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin. Prev Cardiol. 1998; 4:13-20.
5. DeMonaco HJ, Irby BT. Warfarin sodium: "curiouser and curiouser!" MGH [Massachusetts General Hospital] Drug Ther. 1997; 7(8):1-3.
6. Meyer M, Chan K, Bolton S. Generic warfarin: implications for patient care - another view. Pharmacotherapy. 1998; 18:884-6.